Key terms
About AVTX
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AVTX news
Apr 16
7:24am ET
Oppenheimer more bullish on Avalo Therapeutics, upgrades to Outperform
Apr 16
6:53am ET
Avalo Therapeutics upgraded to Outperform from Perform at Oppenheimer
Apr 02
7:07am ET
Avalo Therapeutics appoints Kantoff, Goldman, Truex as independent directors
Mar 28
6:22am ET
Avalo Therapeutics’ Strategic Expansion and Leadership Revamp
Mar 27
4:28pm ET
Avalo Therapeutics up 227% afterhours at $15.60 after announcing AlmataBio deal
Mar 27
4:18pm ET
Avalo Therapeutics to sell 12M shares at $5.80 in private placement
Mar 27
4:12pm ET
Avalo Therapeutics acquires anti-IL-1ss mAb in stock-for-stock transaction
No recent press releases are available for AVTX
AVTX Financials
Key terms
Ad Feedback
AVTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AVTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
